CardioDynamics International Corporation --CDIC-- Receives Nasdaq National Market System Listing.

Business Editors and Health/Medical Writers

SAN DIEGO--(BW HealthWire)--May 23, 2000

Medical Technology & Information Solutions Company Increases

Exposure to Larger, More Diversified Group of Institutional and

Individual Investors

CardioDynamics International Corporation (Nasdaq: CDIC), manufacturer of BioZ(R) noninvasive digital cardiac function monitoring systems, today announced that the Company has been approved to begin trading on the Nasdaq-Amex National Market System (NMS). The Company is moving onto the NMS from the Nasdaq Small Cap Market while retaining the same ticker symbol: CDIC. Trading on the new exchange should enable the Company to address a broader investor base, increase the liquidity of its stock, and develop additional financial partnerships.

"Clearly the NMS listing is a milestone achievement for CardioDynamics and represents recognition of our Company's continued growth and success in delivering innovative, cost-effective technology to the medical marketplace," stated Michael K. Perry, CardioDynamics' Chief Executive Officer. "We are extremely pleased to have passed the stringent requirements for the NMS listing. This listing will significantly increase the visibility of our Company and strengthen our position as a leader in the noninvasive cardiac monitoring industry. We look forward to introducing our Company to a much larger and more diversified group of institutional and individual investors. Since many institutions can only invest in companies listed on a major exchange, we believe this will considerably increase the ability of institutional investors to purchase our stock."

As the world's first electronic stock market, Nasdaq set a precedent for technological trading innovation. Nasdaq-Amex Stock Market is the market of choice for business industry leaders worldwide, and creates a unique dual market structure that provides substantial benefits to investors, companies, and member firms of all sizes.

CardioDynamics, with headquarters in San Diego, is a medical technology and information solutions company committed to fundamentally changing the way hemodynamic monitoring is performed in healthcare. The Company's primary products, the BioZ(R) System and BioZ.com(R), utilize Impedance Cardiography (ICG) to noninvasively provide medical professionals with hemodynamic data not previously available in the physician's office and many hospital settings. Just as Electrocardiography (ECG) measures the heart's electrical characteristics, ICG makes it possible to noninvasively measure the heart's mechanical (blood flow) characteristics. Physicians around the world are currently using the BioZ products, including major medical centers such as the Mayo Clinic (Rochester), Stanford University School of Medicine, (Palo Alto), University of California San Francisco (San Francisco), Yale New Haven Hospital (New Haven), and Baylor College of Medicine (Houston). The worldwide market potential for BioZ products is estimated to be $5 billion, together with an additional $800 million in recurring annual revenue for disposables. For additional information, please refer to the company's Web site at www.cdic.com.

Forward-Looking (Safe Harbor) Statement:

Note: Except for the historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which are necessarily subject to uncertainties and risks, which include sole dependence on the BioZ product line, competition from Baxter Healthcare Corp. (manufacturer of the Swan-Ganz(R) device), further capital requirements, and various uncertainties characteristic of companies just emerging from the development stage; as well as other risks detailed in the company's filings with the SEC, including its 1999 Form 10-KSB. The company does not undertake to update the disclosures contained in this press release.